Blurbs

Analysts Offer Insights on Healthcare Companies: Zentalis Pharmaceuticals (ZNTL) and Y-Mabs Therapeutics (YMAB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zentalis Pharmaceuticals (ZNTLResearch Report) and Y-Mabs Therapeutics (YMABResearch Report) with bullish sentiments.

Zentalis Pharmaceuticals (ZNTL)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Zentalis Pharmaceuticals, with a price target of $120.00. The company’s shares closed last Friday at $33.97, close to its 52-week low of $31.70.

According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.3% and a 37.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals.

Zentalis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $95.67, representing a 98.4% upside. In a report issued on April 6, Wells Fargo also initiated coverage with a Buy rating on the stock with a $67.00 price target.

See the top stocks recommended by analysts >>

Y-Mabs Therapeutics (YMAB)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Y-Mabs Therapeutics, with a price target of $63.00. The company’s shares closed last Friday at $13.05.

According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -23.7% and a 20.6% success rate. Burns covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Springworks Therapeutics.

Y-Mabs Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $42.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ZNTL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos